fbpx

Nyheder

Lundbeckfonden Ventures nyheder

  Lund, SWEDEN, BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic replacement surgeries, today announced the appointment of Andreas Muchowski to the position of Vice President of Sales Germany. Andreas will lead sales recruiting efforts and prepare for the upcoming market launch of exciting...
Sunnyvale, CA, Asante Solutions, Inc. (Asante), a medical device company focused on diabetes care, has strengthened its leadership team by adding David Thrower as president and chief executive officer, and Eric Steuben as vice president of operations. Former President and Chief Executive Officer Phil Hopper will remain as a special advisor and board member.  ...
LUND, Sweden, April 4, 2012 /PRNewswire/   BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgeries, today revealed details of a One Hundred Day Plan presented by Chief Executive Officer Lloyd Diamond. Mr. Diamond addresses key initiatives aimed at accelerating global commercialization of the...
BURLINGTON, MA (April 2, 2012): AlloCure, Inc., a clinical stage biotechnology company focused on the treatment of kidney disease, today announced the closing of a $25 million Series B venture financing. The round included the participation of new syndicate member Lundbeckfond Ventures, as well as previous investors SV Life Sciences and Novo A/S. AlloCure also...
  Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that enrolment has been completed in its pivotal LCP-Tacro Phase III study in de novo kidney transplant patients. The LCP-Tacro 3002 study is designed to demonstrate non-inferiority versus the gold standard therapy Prograf® and has randomized over 540 patients at approximately 90 clinical sites around the world....
BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced the launch of a new corporate web site. The new web site aims to update the BONESUPPORT brand while providing increased educational and clinical CERAMENTT content to an expanding audience. “Our business has...
Funding enables further development of unique metagenomic technology and solutions for gut microbiota-related diseases affecting a large proportion of world populationParis, March 22, 2012 – Enterome, a stratified medicine company developing biomarkers for chronic and challenging medical conditions relating to abnormalities of bacterial composition of the human intestine (metabolic and bowel diseases), today announces a...
  Viaskin Peanut, the first epicutaneous skin patch for the treatment of peanut allergy, is recognized as a unique and promising desensitization product   BAGNEUX, France, February 28, 2012 – DBV Technologies announced today that it has received Fast Track Designation” for the Clinical Development Program of its Viaskin® Peanut, a product designed for the...
1 63 64 65 66 67 68

Lundbeckfonden Ventures

Nyheder

Subgroup Analyses from Sanifit’s CaLIPSO Phase 2b Clinical Study Published in Kidney International Reports
11. november 2020
Acacia Pharma Group PLC – Acacia Pharma completes drawdown from €25 million loan facility from Cosmo Pharmaceuticals to support US launches of BARHEMSYS® and BYFAVO™
9. oktober 2020
Acacia Pharma Group PLC – Acacia Pharma announces BYFAVO™ (remimazolam), its Newly Approved Product for Procedural Sedation, Clears Final Hurdle on Path to Commercial Launch in the US
7. oktober 2020